Results 11 to 20 of about 27,163 (253)
Neurology Clinical Practice, 2011 Fingolimod is the first oral disease therapy approved for relapsing-remitting multiple sclerosis (MS). Patients can be switched directly from interferon-β or glatiramer acetate to fingolimod without a washout period. Fingolimod's potent efficacy, oral route of administration, and generally good safety and tolerability make it appealing to patients and ...
Megan H, Hyland, Jeffrey A, Cohen
openaire +2 more sources
The antiinflammatory and electrophysiological effects of fingolimod on penicillin-induced rats
Arquivos de Neuro-Psiquiatria, 2022 Background The fact that inflammation triggers epileptic seizures brings to mind the antiepileptic properties of anti-inflammatory drugs. Objective To investigate the electrophysiological and anti-inflammatory effects of fingolimod on an ...
Canan Akünal Türel +4 more
doaj +1 more source
Fingolimod‐induced bladder lymphoma in a patient with multiple sclerosis
Clinical Case Reports, 2023 Key Clinical Message Malignancies were reported in some studies following taking Fingolimod. We reported a case of bladder lymphoma after taking Fingolimod. Physicians should consider the carcinogenic effects of Fingolimod in long‐term use and replace it
Saeed Vaheb +3 more
doaj +1 more source
Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis. [PDF]
PLoS ONE, 2015 OBJECTIVE: Effect of fingolimod in multiple sclerosis (MS) is thought to involve the prevention of lymphocyte egress from lymphoid tissues, thereby reducing autoaggressive lymphocyte infiltration into the central nervous system across blood-brain barrier
Hideaki Nishihara +7 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Preclinical data indicate that fingolimod improves outcome post-ischaemia. This study used a rigorous study design in normal male C57BL/6JOlaHsd mice and in mice with common stroke comorbidities to further evaluate the translational potential of ...
Andrea C. Diaz Diaz +6 more
doaj +1 more source
Frontiers in Neuroscience, 2021 Favorable effects exerted by long-term administration of fingolimod therapy in multiple sclerosis (MS) patients have been reported, but sporadic side effects, such as reversible macular edema, also have been recorded. The present study aimed to determine
Tao Yang +8 more
doaj +1 more source
Exploratory Research in Clinical and Social Pharmacy, 2021 Background: Fingolimod is the first approved oral disease-modifying agent (DMA) in 2010 to treat Multiple Sclerosis (MS). There is limited real-world evidence regarding the determinants associated with fingolimod use in the early years.
Jagadeswara Rao Earla +5 more
doaj +1 more source
A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project. [PDF]
, 2020 Neurologists managing women with Multiple Sclerosis (MS) need information about the safety of disease modifying drugs (DMDs) during pregnancy. However, this knowledge is limited.
A Haghikia +20 more
core +1 more source
Fingolimod Promotes Antibacterial Effect of Doripenem against Carbapenem-Resistant Escherichia coli
Antibiotics, 2022 The aim of this study was to determine whether fingolimod could synergize the antibacterial activity of doripenem against carbapenem-resistant Escherichia coli (CREC) and its potential as an antibiotic adjuvant for doripenem. The E.
Hye-Won Jin, Hye-Rim Kim, Yong-Bin Eom
doaj +1 more source
Fingolimod Therapy for Pediatric Relapsing-Remitting Multiple Sclerosis: A Real-Life Study
Türk Nöroloji Dergisi, 2020 Objective: Clinical studies in childhood multiple sclerosis (MS) are very limited compared with adults. Although first-line injection therapies are well tolerated in this patient group, there are difficulties in the long-term treatment of patients due to
Canan Duman İlki +5 more
doaj +1 more source